Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GKB OphthalmicsNSE:GKB 44 Equity-to-Asset is 0.00 as of Jun. 2026. GuruFocus rates NSE:GKB with a GF Score™ of 44/100 and a GF Value™ of ₹126.23 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 851 Medical Devices & Instruments companies, GKB Ophthalmics ranks worse than 76.03% on this metric.
The historical rank and industry rank for GKB Ophthalmics's Equity-to-Asset or its related term are showing as below:
NSE:GKB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37 Med: 0.56 Max: 0.59
Current: 0.4
During the past 13 years, the highest Equity to Asset Ratio of GKB Ophthalmics was 0.59. The lowest was 0.37. And the median was 0.56.
NSE:GKB's Equity-to-Asset is ranked worse than 76.03% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs NSE:GKB: 0.40
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
GKB Ophthalmics Equity-to-Asset Related Terms
GKB Ophthalmics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for GKB Ophthalmics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GKB vs ISRG, BDX, MDLN: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, GKB Ophthalmics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GKB Ophthalmics Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GKB Ophthalmics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where GKB Ophthalmics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
GKB Ophthalmics's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKB Ophthalmics (NSE:GKB) has a Equity-to-Asset of 0.00 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on GKB Ophthalmics and its competitors. Over the past decade, GKB Ophthalmics' Equity-to-Asset has ranged from 0.37 to 0.59. According to the industry distribution chart, GKB Ophthalmics ranks #647 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 76%.
Is GKB Ophthalmics' Equity-to-Asset too high?
GKB Ophthalmics' current Equity-to-Asset is 0.00. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 0.59. Based on the distribution chart, GKB Ophthalmics ranks #647 out of 851 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, GKB Ophthalmics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GKB Ophthalmics' Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, GKB Ophthalmics ranks #647 out of 851 companies for Equity-to-Asset. This places GKB Ophthalmics in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Historically, GKB Ophthalmics' own Equity-to-Asset has ranged from 0.37 to 0.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on GKB Ophthalmics and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GKB Ophthalmics's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GKB Ophthalmics stock overvalued right now?
Based on GuruFocus' analysis, GKB Ophthalmics (NSE:GKB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹126.23, compared to a current price of ₹63.00 — trading 50.1% below its estimated fair value. The current Equity-to-Asset is 0.00. GKB Ophthalmics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For GKB Ophthalmics (NSE:GKB), the current Equity-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GKB Ophthalmics (NSE:GKB) Overvalued in 2026?
Based on GuruFocus' analysis, GKB Ophthalmics stock appears to be undervalued.
The current stock price of ₹63.00 is trading 50.1% below its estimated GF Value™ of ₹126.23.
GuruFocus considers GKB Ophthalmics to be Significantly Undervalued.
Key valuation signals for NSE:GKB:
Equity-to-Asset: 0.00
GF Value™: ₹126.23 vs. price of ₹63.00 (50.1% below fair value)
No single metric tells the full story. See the NSE:GKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GKB Ophthalmics Ltd is an India-based company engaged in manufacturing and exporting ophthalmics lenses. It manufactures glass and plastic lenses both semi-finished and finished forms. The other products of the company include Organic lenses, Glass moulds, and Bifocal moulds. The company sells its products in India and also exports globally. Geographically, the majority of its revenue is generated from outside of India.
44GF Score
Get the complete analysis for NSE:GKB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKB has been successfully added to your 
